Illumina, Inc. reported second quarter fiscal year 2026 financial results on July 30, 2026, for the period ended June 28, 2026. The company generated $1.16 billion in revenue, representing a 9.5% increase from the prior year and an 8.1% organic growth rate excluding currency, acquisitions, and China impacts. GAAP diluted earnings per share were $1.35, while non-GAAP diluted EPS reached $1.31. Illumina raised its full-year fiscal 2026 revenue guidance to a range of $4.60-$4.64 billion from the previous estimate of $4.52-$4.62 billion and increased non-GAAP diluted EPS guidance to $5.30-$5.40 from $5.15-$5.30. The company operates in the genomics industry, providing DNA sequencing and array-based technologies for research, clinical, and applied markets.
